Accrued Liabilities, Current of UNITED THERAPEUTICS Corp from 30 Jun 2010 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
UNITED THERAPEUTICS Corp quarterly Accrued Liabilities, Current in USD history and change rate from 30 Jun 2010 to 31 Dec 2024.
  • UNITED THERAPEUTICS Corp Accrued Liabilities, Current for the quarter ending 31 Dec 2024 was $338,500,000, a 16% increase year-over-year.
Source SEC data
View on sec.gov
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Change (%)

UNITED THERAPEUTICS Corp Quarterly Accrued Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $338,500,000 +$46,100,000 +16% 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q4 2023 $292,400,000 +$66,600,000 +29% 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q4 2022 $225,800,000 +$55,000,000 +32% 31 Dec 2022 10-K 21 Feb 2024 2023 FY
Q4 2021 $170,800,000 -$12,100,000 -6.6% 31 Dec 2021 10-K 22 Feb 2023 2022 FY
Q4 2020 $182,900,000 +$44,400,000 +32% 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q4 2019 $138,500,000 -$4,500,000 -3.1% 31 Dec 2019 10-K 24 Feb 2021 2020 FY
Q4 2018 $143,000,000 -$19,700,000 -12% 31 Dec 2018 10-K 26 Feb 2020 2019 FY
Q4 2017 $162,700,000 +$66,600,000 +69% 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q4 2016 $96,100,000 +$200,000 +0.21% 31 Dec 2016 10-K 21 Feb 2018 2017 FY
Q4 2015 $95,900,000 +$17,513,000 +22% 31 Dec 2015 10-K 22 Feb 2017 2016 FY
Q4 2014 $78,387,000 -$7,149,000 -8.4% 31 Dec 2014 10-K 25 Feb 2016 2015 FY
Q4 2013 $85,536,000 +$12,551,000 +17% 31 Dec 2013 10-K 24 Feb 2015 2014 FY
Q2 2013 $81,727,000 +$14,516,000 +22% 30 Jun 2013 10-Q 25 Jul 2013 2013 Q2
Q1 2013 $67,338,000 +$8,748,000 +15% 31 Mar 2013 10-Q 25 Apr 2013 2013 Q1
Q4 2012 $72,985,000 +$15,758,000 +28% 31 Dec 2012 10-K 25 Feb 2014 2013 FY
Q3 2012 $87,635,000 +$18,007,000 +26% 30 Sep 2012 10-Q 01 Nov 2012 2012 Q3
Q2 2012 $67,211,000 +$5,256,000 +8.5% 30 Jun 2012 10-Q 26 Jul 2012 2012 Q2
Q1 2012 $58,590,000 +$5,772,000 +11% 31 Mar 2012 10-Q 26 Apr 2012 2012 Q1
Q4 2011 $57,227,000 +$6,947,000 +14% 31 Dec 2011 10-K 26 Feb 2013 2012 FY
Q3 2011 $69,628,000 +$24,086,000 +53% 30 Sep 2011 10-Q 27 Oct 2011 2011 Q3
Q2 2011 $61,955,000 +$20,066,000 +48% 30 Jun 2011 10-Q 28 Jul 2011 2011 Q2
Q1 2011 $52,818,000 31 Mar 2011 10-Q 28 Apr 2011 2011 Q1
Q4 2010 $50,280,000 31 Dec 2010 10-K 28 Feb 2012 2011 FY
Q3 2010 $45,542,000 30 Sep 2010 10-Q 28 Oct 2010 2010 Q3
Q2 2010 $41,889,000 30 Jun 2010 10-Q 28 Jul 2010 2010 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.